Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Sonnet BioTherapeutics Holdings ( (SONN) ) is now available.
On May 30, 2025, Sonnet BioTherapeutics Holdings received a deficiency notice from Nasdaq for not meeting the $2.5 million minimum stockholders’ equity requirement. However, by July 18, 2025, the company reported raising sufficient funds through private placement and warrant exercises, ensuring compliance with Nasdaq’s equity rule. On July 23, 2025, Nasdaq confirmed the company’s compliance but will continue to monitor its financial status, with potential delisting if future requirements are not met.
The most recent analyst rating on (SONN) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Sonnet BioTherapeutics Holdings stock, see the SONN Stock Forecast page.
Spark’s Take on SONN Stock
According to Spark, TipRanks’ AI Analyst, SONN is a Neutral.
Sonnet BioTherapeutics Holdings faces significant financial challenges, reflected in a low financial performance score. Technical indicators provide a slightly more optimistic picture, but the valuation remains a concern due to ongoing losses. Recent corporate actions, while positive, are not factored into the overall score calculation.
To see Spark’s full report on SONN stock, click here.
More about Sonnet BioTherapeutics Holdings
Sonnet BioTherapeutics Holdings operates in the biotherapeutics industry, focusing on developing innovative biologic drugs for cancer and other diseases. The company is engaged in creating targeted therapies that aim to improve patient outcomes.
Average Trading Volume: 3,854,013
Technical Sentiment Signal: Sell
Current Market Cap: $26.43M
For detailed information about SONN stock, go to TipRanks’ Stock Analysis page.